KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $208.2 million.

  • Idexx Laboratories' Cash & Equivalents fell 3255.29% to $208.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.2 million, marking a year-over-year decrease of 3255.29%. This contributed to the annual value of $288.3 million for FY2024, which is 3649.58% down from last year.
  • Latest data reveals that Idexx Laboratories reported Cash & Equivalents of $208.2 million as of Q3 2025, which was down 3255.29% from $164.6 million recorded in Q2 2025.
  • Over the past 5 years, Idexx Laboratories' Cash & Equivalents peaked at $453.9 million during Q4 2023, and registered a low of $99.2 million during Q3 2022.
  • Over the past 5 years, Idexx Laboratories' median Cash & Equivalents value was $204.6 million (recorded in 2022), while the average stood at $229.8 million.
  • Within the past 5 years, the most significant YoY rise in Idexx Laboratories' Cash & Equivalents was 33143.07% (2021), while the steepest drop was 6237.47% (2021).
  • Idexx Laboratories' Cash & Equivalents (Quarter) stood at $144.5 million in 2021, then fell by 22.09% to $112.5 million in 2022, then skyrocketed by 303.33% to $453.9 million in 2023, then plummeted by 36.5% to $288.3 million in 2024, then decreased by 27.79% to $208.2 million in 2025.
  • Its Cash & Equivalents stands at $208.2 million for Q3 2025, versus $164.6 million for Q2 2025 and $164.0 million for Q1 2025.